Related Experiment Video
Updated: Jul 13, 2025

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing
Stefania Napolitano1,2, Aparna R Parikh3, Jason Henry4
1Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
A new statistical model helps clinicians assess the accuracy of circulating tumor DNA (ctDNA) tests for detecting RAS mutations in metastatic colorectal cancer. This tool quantifies the probability of false negatives, improving treatment decisions when RAS mutation status is uncertain.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biostatistics
Background:
- Circulating tumor DNA (ctDNA) testing offers a noninvasive method for determining RAS mutation status in metastatic colorectal cancer.
- However, false-negative results in ctDNA testing can occur, potentially impacting critical treatment choices.
- Accurate assessment of RAS mutational status is crucial for guiding targeted therapy in colorectal cancer.
Purpose of the Study:
- To develop and validate a statistical model for assessing the probability of false-negative results in ctDNA-based RAS mutation detection.
- To provide clinicians with a tool to better interpret ctDNA results and mitigate risks associated with missed mutations.
- To enhance the reliability of noninvasive molecular diagnostics in oncology.
Main Methods:
- A Bayesian statistical model was developed using ctDNA data from two independent cohorts (n=172 and n=146).
- The model utilizes the frequencies of reference mutations (APC and TP53) to estimate the probability of KRAS false negatives.
- Model performance was evaluated through cross-cohort validation and simulations, using Guardant assays data.
Main Results:
- The model indicates that negative KRAS findings are reliable (posterior probability of false negative <5%) when the maximum frequency of APC or TP53 mutations is at least 8%.
- Validation studies confirmed the model's ability to accurately distinguish between false-negative and true-negative ctDNA results.
- Simulations demonstrated the practical utility of the proposed statistical approach in real-world clinical scenarios.
Conclusions:
- Clinicians can use this statistical tool to precisely quantify the likelihood of false-negative KRAS ctDNA results, particularly when reference mutation frequencies are below 8%.
- The methodology can be extended to predict false negatives for other genes and incorporate additional reference markers.
- An open-source R Shiny application is available to facilitate the widespread adoption and application of this tool.
More Related Videos
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
10:35A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
Published on: April 5, 2018